Biocatalysis News and Research

RSS

Scientists discover four different bacteria that can live on caffeine

As it turns out, humans aren't the only organisms that turn to caffeine for a pick-me-up. University of Iowa scientists have identified four different bacteria that actually can live on caffeine.

8 Jun 2011

Almac launches six enzyme screening kits

As anticipated, Almac's biocatalysis business has expanded from its 2009 launch with the sale of six enzyme screening kits, to the current supply of 100s of kgs of chiral intermediates for drug substance manufacture, regular enzyme supply to specialty chemical companies and continued growth of its screening kits offering. Biocatalysis is increasingly recognised as an alternative solution for solving complex chemistry problems due to its rapid implementation, economic benefits and 'green' reputation.

4 May 2011

Eviagenics closes financing round for EUR 1.3 million to commercialize its technology platform

Eviagenics, a French biotech company, is pleased to announce the closing of a series A financing round to scale up its technical and commercial development. At this occasion the FCPR Emertec 4 managed by Emertec Management, CEA Investissement, and Genopole Premier Jour managed by CapDecisif Management provide a total contribution of EUR 1.3 million.

9 Feb 2011

Almac opens analytical facility at new 240,000 sq. ft. North American Headquarters

Almac's new 240,000 sq. ft. North American Headquarters, built on 40 acres in Souderton, PA, north of Philadelphia is part of the Almac Group's integrated services solutions strategy. The new facility delivers full-service, integrated clinical packaging, drug supply management and technology solutions to pharmaceutical and biotech clients.

8 Feb 2011

DSM licenses c-LEcta's alcohol dehydrogenases for enzyme screening programs

DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, today announces a license agreement with c-LEcta GmbH for proprietary screening technology.

15 Dec 2010

DSM project on carbon dioxide footprint reduction receives European Outsourcing Awards

DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, is pleased to announce that their submission for the European Outsourcing Awards, organized by Via Media UK Ltd, entitled Achieving substantial carbon dioxide footprint reduction for the scale up of a drug intermediate was an award recipient at the 6th October ceremony held in Paris, France.

7 Oct 2010

EUCODIS Bioscience, evocatal enter alliance to market industrial enzyme products

Industrial biotech companies EUCODIS Bioscience and evocatal today announced the formation of an alliance to jointly market the companies' industrial enzyme products, including alcohol dehydrogenases, lipases, and other enzymes.

5 Oct 2010

DSM Pharma launches InnoSyn route scouting services for pharmaceutical customers

DSM Pharma Chemicals, a business unit of DSM Pharmaceutical Products, today announced the launch of InnoSyn™ route scouting services. In response to the increasing interest of pharmaceutical customers to outsource the development of robust low-cost manufacturing routes, DSM is offering focused and flexible stand alone route scouting services.

7 Sep 2010

Biopharmaceutical firms take steps to create greener working environments

Biopharmaceutical firms and other life science organizations are taking definitive steps toward creating greener working environments and developing more sustainable operations, reports Genetic Engineering & Biotechnology News (GEN).

3 Sep 2010

BRAIN AG acquires a minority share in Enzymicals AG

BRAIN AG, one of the leading European white biotechnology companies, has acquired a minority share in Enzymicals AG. This biotechnology company was founded in 2009 as a spin-off by a management team from the workgroup led by Prof. Dr. Uwe Bornscheuer from Ernst-Moritz-Arndt University Greifswald with support from the EXIST-Programme of the Federal Ministry for Economy and Technology.

12 Jul 2010

Cambrex first-quarter sales down 6.4% to $56.2 million

Cambrex Corporation reports first quarter results for the period ended March 31, 2010.

4 May 2010

Cambrex announces acquisition of IEP GmbH

Cambrex Corporation announced it has acquired IEP GmbH, a privately held company that is a leader in the field of industrial biocatalysis. IEP is located in Wiesbaden, Germany and offers cost effective customized biocatalytic process development and sales of enzymes to the pharmaceutical industry, with the ability to utilize its tool box of over 100 proprietary biocatalytic enzymes.

23 Mar 2010

DSM Pharmaceutical Products wins Profiles in Sustainability award

DSM Pharmaceutical Products, based in Parsippany, NJ, today announced that it has received a Profiles in Sustainability award from United Business Media and ICIS Chemical Business. United Business Media Limited is a leading global business media company and parent of InformexUSA, where the award was announced today in San Francisco.

19 Feb 2010

Codexis signs second agreement with Teva Pharmaceutical Industries

Codexis, Inc. today announced an expansion of its relationship and the signing of its second agreement this year with Teva Pharmaceutical Industries Ltd., the world's largest generic drug manufacturer. The new agreement covers three undisclosed pharmaceutical products.

1 Dec 2009

Researchers to develop a safer and synthetic alternative to current heparin

With a $4.6 million grant from the National Institutes of Health (under the Bioengineering Research Partnership program), research led by Rensselaer Polytechnic Institute will make its important final steps toward the development of a safer, synthetic alternative to current heparin. The researchers believe that kilogram quantities of the new drug could be developed in under five years.

18 Sep 2009

New vaccine technology may prove beneficial for treating IGF-1 responsive disorders

Braasch Biotech LLC announces its lead vaccine for Obesity, Growth Hormone Deficiencies may have beneficial use for numerous IGF-1 responsive disorders such as diabetes, heart disease and Rett Syndrome based on initial preclinical testing in a mouse model.

1 Sep 2009

New flu compound

What happens if the next big influenza mutation proves resistant to the available anti-viral drugs? This question is presenting itself right now to scientists and health officials this week at the World Health Assembly in Geneva, Switzerland, as they continue to do battle with H1N1, the so-called swine flu, and prepare for the next iteration of the ever-changing flu virus.

19 May 2009

Researchers create synthetic heparin

Robert Linhardt has spent years stitching together minuscule carbohydrates to build a more pure and safer alternative to the commonly used and controversial blood thinner heparin. At the national conference of the American Chemical Society on August 17, 2008, Linhardt announced that his research team may have accomplished this task by building the first fully synthetic heparin. Their creation is the largest dose of heparin ever created in the lab.

17 Aug 2008

Discovery of key link that causes malarial infection in both humans and mosquitoes

As summer temperatures cool in the United States, fewer mosquitoes whir around our tiki torches.

30 Aug 2007

Alternative method to produce heparin

Researchers at Rensselaer Polytechnic Institute and University of North Carolina at Chapel Hill have discovered an alternative way to produce heparin, a drug commonly used to stop or prevent blood from clotting.

7 Feb 2006